Trademark Overview
On Monday, October 7, 2024, a trademark application was filed for MAXION with the United States Patent and Trademark Office. The USPTO has given the MAXION trademark a serial number of 79412149. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Thursday, December 12, 2024. This trademark is owned by Maxion Therapeutics Limited. The MAXION trademark is filed in the Chemical Products, Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Pharmaceuticals and pharmaceutical preparations; drugs; antibodies for medical use; pharmaceuticals, drugs and pharmaceutical preparations incorporating antibodies, ion channel blocking antibodies or antibodies derived from mini-protein toxins; vaccines.
Chemicals for use in industry and science; biochemicals, including polypeptides and antibodies for scientific, laboratory or research purposes; polypeptides and antibodies for use in the manufacture of pharmaceuticals and drugs; ion channel blocking antibodies for scientific, laboratory or research purposes; ion channel blocking antibodies for use in the manufacture of pharmaceuticals and drugs; antibodies derived from mini-protein toxins for scientific, laboratory or research purposes; antibodies derived from mini-protein toxins for use in the manufacture of pharmaceuticals and drugs.
Medical services; medical testing, analysis and diagnostic services in the field of antibodies; medical services connected with the treatment of diseases through the use of antibodies, ion channel blocking antibodies or antibodies derived from mini-protein toxins, or pharmaceuticals, drugs and pharmaceutical preparations derived from the aforesaid; information, advisory and consultancy services in relation to all of the aforesaid.
Scientific and technological services and research and design relating thereto; drug discovery and drug development services; conducting or providing research and development services for others in the field of antibodies; laboratory services relating to the production of antibodies, ion channel blocking antibodies or antibodies derived from mini-protein toxins; antibody engineering; scientific services relating to the discovery, preclinical and clinical development of therapeutic products; information, advisory and consultancy services in relation to all of the aforesaid.
